EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome

Jurjen M Ruben, Charlotte M Mousset, Dorien van de Berg, Kim Hofman, Milon de Jong, Patricia Brouwer, Sanne Graeve, Victoria Iglesias-Guimarais, Pauline M van Helden, Anton E P Adang, Rob C Roovers, Hans J van der Vliet

Clinical Immunology · 2026-12 · 288 · 110786

DOI: 10.1016/j.clim.2026.110786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2026-12. Verfasst von Jurjen M Ruben und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, the Netherlands; LAVA Therapeutics N.…. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) have poor outcomes. We developed a humanized, half-life-extended CD123 × Vδ2 bispecific T-cell engager (bsTCE) to redirect Vγ9Vδ2 T cells to CD123-expressing malignancies. The engager bound selectively to Vγ9Vδ2 T cells and CD123-positive AML cells, with no detectable off-target interactions in specificity and tissue cross-reactivity assays. In vitro, it induced potent lysis of tumor cell lines and patient-derived AML and MDS cells, including at low effector-to-target cell ratios, supportive of serial killing. Compared with a CD123 × CD3 bsTCE, it induced lower levels of cytokines associated with cytokine release syndrome. Vγ9Vδ2-T cells preferentially lysed tumor cells over CD123-positive non-malignant cells, including plasmacytoid dendritic cells, and were detectable in patients' peripheral blood and bone marrow. The engager reduced tumor growth in an AML xenograft model and showed antibody-like pharmacokinetics in nonhuman primates. A phase 1 clinical trial was initiated (ACTRN12624001214527).

Schlagwörter

Stichwörter der Autor:innen

Acute myeloid leukemia (AML)Bispecific T cell engagerCD123Cancer immunotherapyMyelodysplastic syndrome (MDS)Tumor-selective cytotoxicityVγ9Vδ2 T cellsγδ T cells

Autor:innen und Institutionen

  • Department of Medical Oncology, Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, the Netherlands; LAVA Therapeutics N.V, Utrecht, the Netherlands; Engager BIO B.V, Amstelveen, the Netherla…
  • LAVA Therapeutics N.V, Utrecht, the Netherlands.
  • Department of Medical Oncology, Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, the Netherlands.
  • LAVA Therapeutics N.V, Utrecht, the Netherlands; Engager BIO B.V, Amstelveen, the Netherlands.

Zitieren

APA

Ruben, J. M., Mousset, C. M., van de Berg, D., Hofman, K., de Jong, M., Brouwer, P., Graeve, S., Iglesias-Guimarais, V., van Helden, P. M., Adang, A. E. P., Roovers, R. C., & van der Vliet, H. J. (2026). A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome. Clinical Immunology, 288, 110786. https://doi.org/10.1016/j.clim.2026.110786

Vancouver

Ruben JM, Mousset CM, van de Berg D, Hofman K, de Jong M, Brouwer P, et al. A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome. Clinical Immunology. 2026;288:110786. doi:10.1016/j.clim.2026.110786

BibTeX
@article{Ruben2026,
  author = {Ruben, Jurjen M and Mousset, Charlotte M and van de Berg, Dorien and Hofman, Kim and de Jong, Milon and Brouwer, Patricia and Graeve, Sanne and Iglesias-Guimarais, Victoria and van Helden, Pauline M and Adang, Anton E P and Roovers, Rob C and van der Vliet, Hans J},
  title = {A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome},
  journal = {Clinical Immunology},
  year = {2026},
  volume = {288},
  pages = {110786},
  doi = {10.1016/j.clim.2026.110786}
}
Kostenlos starten →